SCHEMBL497761

SCHEMBL497761

CCOC(OCC)C(CC(=O)O)c1ccc(OC)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.52
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
ALDH1A1 P00352 3/20 0.49
TNF P01375 1/20 0.49
POLB P06746 2/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 3/20 0.46
ACHE P22303 1/20 0.46
CYP2C19 P33261 1/20 0.45
TSHR P16473 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.43
HIF1A Q16665 1/20 0.43
LDHA P00338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6229093 0.89 PDE4B (0.49) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL6228902 0.89 PDE4A (0.49) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL6227557 0.89 PDE4B (0.49) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL6230314 0.88 PDE4A (0.48) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL6232542 0.87 PDE4A (0.53) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL6231350 0.86 PDE4B (0.48) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL6228583 0.86 PDE4A (0.57) PDE4APDE4BPDE4CPDE4D
SCHEMBL6227492 0.85 PDE4A (0.46) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL6229294 0.85 PDE4A (0.51) SMN1; SMN2PDE4APDE4BPDE4CPDE4D
SCHEMBL6231659 0.83 FFAR1 (0.55) SMN1; SMN2PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2157084-B1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA CO (JP) 2013-05-22 EP disclosed
US-8106053-B2 5-phenyl-3-pyridazinone derivative KOWA COMPANY, LTD. 2012-01-31 US disclosed
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE KOWA COMPANY, LTD. (JP) 2010-08-05 US disclosed
EP-2157084-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE Kowa Company, Ltd. (JP) 2010-02-24 EP disclosed
EP-0933366-B1 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME NIKKEN CHEMICALS CO LTD (JP) 2005-04-06 EP disclosed
US-6235739-B1 ANTIINFLAMMATORY AGENTS; ANTIHISTAMINES; SKIN DISORDERS NIKKEN CHEMICALS CO., LTD. (JP) 2001-05-22 US disclosed
EP-0933366-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME Nikken Chemicals Company, Limited (JP) 1999-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197698-A1 5-PHENYL-3-PYRIDAZINONE DERIVATIVE SERPINE1, MMP1, PLAT SMN1; SMN2 2022/4885PDE4A 2167/4885PDE4B 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.